2022
DOI: 10.1101/2022.09.20.508747
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

Affinity-matured homotypic interactions induce spectrum of PfCSP-antibody structures that influence protection from malaria infection

Abstract: The generation of high-quality antibody responses to PfCSP, the primary surface antigen of Plasmodium falciparum sporozoites, is paramount to the development of an effective malaria vaccine. Here we present an in-depth structural and functional analysis of a panel of potent antibodies encoded by the IGHV3-33 germline gene, which is among the most prevalent and potent antibody families induced in the anti-CSP immune response and targets the NANP repeat region. Cryo-EM reveals a remarkable spectrum of helical … Show more

Help me understand this report
View published versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

1
14
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
4
1

Relationship

4
1

Authors

Journals

citations
Cited by 7 publications
(15 citation statements)
references
References 67 publications
1
14
0
Order By: Relevance
“…S3, A and B). These findings provide strong evidence for affinity maturation to optimize antibody-antibody binding, which may in turn enhance CSP avidity and protective efficacy, as we have shown recently for multiple NPNA-specific IGHV3-33 mAbs (11).…”
Section: Main Textsupporting
confidence: 73%
See 4 more Smart Citations
“…S3, A and B). These findings provide strong evidence for affinity maturation to optimize antibody-antibody binding, which may in turn enhance CSP avidity and protective efficacy, as we have shown recently for multiple NPNA-specific IGHV3-33 mAbs (11).…”
Section: Main Textsupporting
confidence: 73%
“…Notably, these L9K residues (F28, R31, E68, H70) make no direct contacts with rsCSP (fig. S3; table S2), indicating that the minor repeat region facilitates antibody-antibody affinity maturation in the context of multiple adjacent NPNV motifs, as has been observed for extended NPNA repeats (11,18,19). L9 is one of the most potent anti-PfCSP mAbs and is currently undergoing clinical development as a monoclonal therapy for malaria prevention (17).…”
Section: Competing Interestsmentioning
confidence: 82%
See 3 more Smart Citations